1. Home
  2. GKOS vs ITCI Comparison

GKOS vs ITCI Comparison

Compare GKOS & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • ITCI
  • Stock Information
  • Founded
  • GKOS 1998
  • ITCI 2002
  • Country
  • GKOS United States
  • ITCI United States
  • Employees
  • GKOS N/A
  • ITCI N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • ITCI Biotechnology: Pharmaceutical Preparations
  • Sector
  • GKOS Health Care
  • ITCI Health Care
  • Exchange
  • GKOS Nasdaq
  • ITCI Nasdaq
  • Market Cap
  • GKOS 7.4B
  • ITCI 8.0B
  • IPO Year
  • GKOS 2015
  • ITCI N/A
  • Fundamental
  • Price
  • GKOS $145.90
  • ITCI $88.07
  • Analyst Decision
  • GKOS Strong Buy
  • ITCI Strong Buy
  • Analyst Count
  • GKOS 13
  • ITCI 12
  • Target Price
  • GKOS $143.00
  • ITCI $97.67
  • AVG Volume (30 Days)
  • GKOS 496.0K
  • ITCI 399.6K
  • Earning Date
  • GKOS 11-04-2024
  • ITCI 10-30-2024
  • Dividend Yield
  • GKOS N/A
  • ITCI N/A
  • EPS Growth
  • GKOS N/A
  • ITCI N/A
  • EPS
  • GKOS N/A
  • ITCI N/A
  • Revenue
  • GKOS $360,347,000.00
  • ITCI $613,728,000.00
  • Revenue This Year
  • GKOS $22.68
  • ITCI $48.26
  • Revenue Next Year
  • GKOS $24.98
  • ITCI $38.45
  • P/E Ratio
  • GKOS N/A
  • ITCI N/A
  • Revenue Growth
  • GKOS 18.70
  • ITCI 46.08
  • 52 Week Low
  • GKOS $74.75
  • ITCI $62.78
  • 52 Week High
  • GKOS $147.65
  • ITCI $93.45
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 58.40
  • ITCI 61.65
  • Support Level
  • GKOS $137.60
  • ITCI $82.14
  • Resistance Level
  • GKOS $147.50
  • ITCI $84.31
  • Average True Range (ATR)
  • GKOS 4.74
  • ITCI 2.19
  • MACD
  • GKOS 0.45
  • ITCI 0.06
  • Stochastic Oscillator
  • GKOS 87.80
  • ITCI 87.81

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

About ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Share on Social Networks: